Q3 Earnings Estimate for Shattuck Labs Issued By Wedbush

Key Points

• Wedbush forecasts Shattuck Labs, Inc. to post Q3 2025 earnings of ($0.11) per share, with a full-year estimate of ($1.48) EPS and an "Outperform" rating with a target price of $4.00.
• Recent analyst reports indicate mixed ratings, with two firms giving a Strong Buy and Buy ratings, while others have issued a Hold rating, resulting in an average rating of Moderate Buy.
• Insider activity has increased as Director Mona Ashiya purchased 6.3 million shares at $0.87 each, indicating significant confidence in the company's future.

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Analysts at Wedbush issued their Q3 2025 earnings per share estimates for shares of Shattuck Labs in a report released on Monday, September 8th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.11) per share for the quarter. Wedbush currently has a "Outperform" rating and a $4.00 price target on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.48) per share. Wedbush also issued estimates for Shattuck Labs' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.39) EPS.

A number of other research analysts also recently commented on STTK. Leerink Partners lowered their price objective on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Wall Street Zen upgraded Shattuck Labs to a "hold" rating in a research note on Friday, September 5th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $4.00.

Shattuck Labs Trading Down 3.0%

STTK traded down $0.06 during trading on Wednesday, reaching $1.92. 252,083 shares of the company were exchanged, compared to its average volume of 1,614,250. The stock has a market cap of $91.97 million, a P/E ratio of -1.59 and a beta of 1.64. The firm has a 50 day moving average of $1.00 and a 200 day moving average of $1.01. Shattuck Labs has a 52 week low of $0.69 and a 52 week high of $3.95.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in Shattuck Labs by 9.2% during the fourth quarter. Northern Trust Corp now owns 353,616 shares of the company's stock valued at $428,000 after buying an additional 29,870 shares in the last quarter. AQR Capital Management LLC boosted its stake in Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after buying an additional 31,355 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Shattuck Labs during the fourth quarter valued at about $45,000. 683 Capital Management LLC boosted its stake in Shattuck Labs by 4.3% during the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company's stock valued at $867,000 after buying an additional 45,000 shares in the last quarter. Finally, Nuveen LLC bought a new position in Shattuck Labs during the first quarter valued at about $50,000. Institutional investors own 58.74% of the company's stock.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, Director Mona Ashiya purchased 6,306,127 shares of the firm's stock in a transaction dated Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the purchase, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. This trade represents a -600.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc purchased 6,306,127 shares of the firm's stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the purchase, the director owned 5,255,106 shares of the company's stock, valued at approximately $4,571,942.22. This represents a -600.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 12.00% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.